Summary of Mindray's Earnings Review for 1H25 Company Overview - **Company**: Mindray (300760.SZ) - **Industry**: Medical Technology (Medtech) Device Manufacturing Key Financial Results - **1H25 Revenue**: Decreased by 18.4% year-over-year (yoy) to Rmb8,506 million, which was 7.4% lower than Goldman Sachs estimates (GSe) [1][2] - **China Revenue**: Decreased by 33.4% yoy, with a significant drop of 42.4% in 2Q25 compared to 22.4% in 1Q25 [1][2] - **Overseas Revenue**: Grew by 5.4% yoy, but only 6.3% in 2Q25, which was below expectations [1][2] - **1H25 Earnings**: Reported at Rmb5,069 million, down 33.0% yoy and 22.9% below GSe [1][16] Segment Performance - **Patient Monitoring and Life Support (PMLS)**: - Revenue decreased by 64% yoy in 2Q25 [2][6] - GPM (Gross Profit Margin) fell to 60.6% in 1H25 from 62.6% in 2024 due to price competition [17] - **Medical Imaging (MI)**: - Revenue decreased by 66% yoy in 2Q25 [2][6] - GPM decreased to 65.1% in 1H25 from 66.9% in 2024 [17] - **In Vitro Diagnostics (IVD)**: - Revenue decreased by 30% yoy in 2Q25 [2][6] - GPM fell to 59.5% in 1H25 from 62.0% in 2024 [17] Inventory and Market Dynamics - **Channel Inventory Destocking**: Accelerated in 2Q25, particularly in the PMLS segment, to mitigate inventory risks [2][9] - **Procurement Activities**: Remained strong in April to June, indicating potential recovery in demand [2] Future Guidance - **Revenue Growth**: Expected to turn positive in 3Q25, with a turning point for China revenue anticipated in the same quarter [1][2] - **Overseas Revenue Growth**: Expected to accelerate, driven by the IVD business [1][2] Long-term Strategy - **Overseas Market Expansion**: Targeting to achieve similar market share in emerging markets as in China, with a focus on recurring business [18] - **Product Focus**: Emphasis on minimally-invasive consumables and animal care products, with expected sales ramp-up for ultrasonic scalpel and stapler in 2025 [18] Valuation and Estimates - **Revised Profit Estimates**: Net profit estimates revised down by 7.7% for 2025E due to faster inventory destocking and lower GPM [19] - **Price Target**: Adjusted to Rmb296 from Rmb300, reflecting near-term estimate cuts but long-term growth expectations [20] Investment Thesis - **Market Position**: Mindray is a leading medtech device manufacturer in China, with strong growth potential in both domestic and overseas markets [22] - **Risks**: Key risks include further impacts from Value-Based Procurement (VBP), challenges in entering North American and European markets, and potential patent-related lawsuits [23] Conclusion - **Recommendation**: Maintain a Buy rating on Mindray, with expectations of recovery in procurement activities and new product launches serving as key catalysts for growth [22]